Caribou Biosciences Announces Presentation of chRDNA Platform Data at the 25th Annual Meeting of the American Society for Gene and Cell Therapy (ASGCT)
May 02 2022 - 4:30PM
Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage
CRISPR genome-editing biopharmaceutical company, today announced
that the company will present studies highlighting the mechanism
underlying the superior specificity of its CRISPR hybrid RNA-DNA
guides (chRDNA) for genome editing of primary human T cells. The
data are being presented at the 25th Annual Meeting of the American
Society for Gene and Cell Therapy (ASGCT), which is being held May
16-19, 2022 in Washington, D.C.
Details of the poster presentation are as
follows:Title: Conformational control of
Cas endonucleases by CRISPR hybrid RNA-DNA guides mitigates
off-target activity in T cellsPresenter: Paul
DonohoueSession Date/Time: Monday, May 16, 2022,
5:30 - 6:30 pm EDTSession Title: Gene Targeting
and Gene Correction IRoom: Hall DPoster
Board Number: M-58Final abstract number:
177
Accepted abstracts are available on the ASGCT website.
About Caribou’s Novel Next-Generation CRISPR
PlatformCRISPR genome editing uses easily designed,
modular biological tools to make DNA changes in living cells. There
are two basic components of Class 2 CRISPR systems: the nuclease
protein that cuts DNA and the RNA molecule(s) that guide the
nuclease to generate a site-specific, double-stranded break,
leading to an edit at the targeted genomic site. CRISPR systems are
capable of editing unintended genomic sites, known as off-target
editing, which may lead to harmful effects on cellular function and
phenotype. In response to this challenge, Caribou has developed
CRISPR hybrid RNA-DNA guides (chRDNAs; pronounced “chardonnays”)
that direct substantially more precise genome editing compared to
all-RNA guides. Caribou is deploying the power of its Cas12a chRDNA
technology to carry out high efficiency multiple edits, including
multiplex gene insertions, to develop CRISPR-edited therapies.
About Caribou Biosciences,
Inc.Caribou Biosciences is a clinical-stage CRISPR
genome-editing biopharmaceutical company dedicated to developing
transformative therapies for patients with devastating diseases.
The company’s genome-editing platform, including its proprietary
Cas12a chRDNA technology, enables superior precision to develop
cell therapies that are specifically engineered for enhanced
persistence. Caribou is advancing a pipeline of off-the-shelf CAR-T
and CAR-NK cell therapies for the treatment of patients with
hematologic malignancies and solid tumors.
Follow us @CaribouBio and visit www.cariboubio.com.“Caribou
Biosciences” and the Caribou logo are registered trademarks of
Caribou Biosciences, Inc.
Forward-Looking StatementsThis
press release contains forward-looking statements, within the
meaning of the Private Securities Litigation Reform Act of 1995.
These forward-looking statements include, without limitation,
statements related to Caribou’s strategy, plans and objectives, and
expectations regarding its clinical and preclinical development
programs. Management believes that these forward-looking statements
are reasonable as and when made. However, such forward-looking
statements are subject to risks and uncertainties, and actual
results may differ materially from any future results expressed or
implied by the forward-looking statements. Risks and uncertainties
include without limitation the risks inherent in drug development
such as those associated with being in the early stages of our
clinical development, and with the initiation, cost, timing,
progress and results of current and future research and development
programs, preclinical studies, and clinical trials, as well as
other risk factors described from time to time in Caribou’s filings
with the Securities and Exchange Commission, including its Annual
Report on Form 10-K for the year ended December 31, 2021. In light
of the significant uncertainties in these forward-looking
statements, you should not rely upon forward-looking statements as
predictions of future events. Except as required by law, Caribou
undertakes no obligation to update publicly any forward-looking
statements for any reason.
Caribou Biosciences,
Inc.Contacts:Amy Figueroa, CFAInvestor Relations and
CorporateCommunicationsafigueroa@cariboubio.com
Investors and Media:Elizabeth
Wolffe, Ph.D., and Sylvia WheelerWheelhouse
LSAlwolffe@wheelhouselsa.comswheeler@wheelhouselsa.com
Caribou Biosciences (NASDAQ:CRBU)
Historical Stock Chart
From Jun 2024 to Jul 2024
Caribou Biosciences (NASDAQ:CRBU)
Historical Stock Chart
From Jul 2023 to Jul 2024